Hangzhou Jiuyuan Genetic Biopharmaceutical Announces Extraordinary General Meeting: Key Resolutions That May Impact Shareholders

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Stock Code: 2566) has issued a formal notice for its Extraordinary General Meeting (EGM), scheduled for Wednesday, April 8, 2026, at 2:30 p.m., to be held at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Hangzhou City, Qiantang District, Zhejiang Province, PRC.

Key Resolutions to Be Considered

• Adoption of the 2026 Share Award Scheme: The company is proposing to introduce a new share award scheme for 2026. This scheme could potentially influence the company’s equity structure and employee incentives, which may affect both operational performance and share value.
• Scheme Mandate Limit: Shareholders will vote on the maximum number of shares that may be awarded under the 2026 Share Award Scheme. Mandate limits are critical as they determine the potential dilution effect on existing shareholders.
• Service Provider Sublimit: A sublimit for service providers under the scheme will be considered. This restricts the portion of awards that may go to service providers rather than employees, which could influence stakeholder interests and company expense profiles.
• Authorization to the Board: The Board (and/or its authorized person) seeks approval to handle all matters relating to the 2026 Share Award Scheme. This grants the Board flexibility to manage scheme implementation without further shareholder approval, which may be significant for investors monitoring corporate governance.

Board Composition

The Board consists of a mix of executive, non-executive, and independent non-executive directors, including prominent names such as Fu Hang (Chairman and General Manager), Zhou Wei, Wu Shihang, Albert Esteve Cruella, Fei Junjie, Yan Weiting, Zhou Zhihui, Ho Mei Yi, and Dr. Zhou Demin. Investors may want to note the leadership structure as it can impact decision-making regarding the share award scheme and other governance issues.

Important Information for Shareholders

• Eligibility and Proxy Voting: All shareholders are eligible to attend and vote at the EGM. Shareholders can appoint one or more proxies to attend and vote on their behalf, and proxies do not need to be shareholders themselves. This flexibility ensures broad participation in these critical decisions.
• Poll Voting: All resolutions at the EGM will be decided by poll, ensuring transparency and equal voting rights per share held.
• Register Closure: The register of members will be closed from March 31, 2026, to April 8, 2026. No transfers will be registered during this period. For H Shareholders, properly completed share transfer forms and relevant certificates must be lodged by 4:30 p.m. on March 30, 2026 to qualify for voting.
• Documentation Requirements: Shareholders or proxies attending the EGM must provide identification documents. Corporate shareholders must provide a resolution authorizing their proxy or representative.
• Joint Holders: In cases of joint shareholding, the vote of the senior joint shareholder will be accepted, determined by the order of names in the register.
• Expense Responsibility: Shareholders attending the EGM (in person or by proxy) shall bear their own travel and accommodation expenses.

Potential Price-Sensitive Implications

The 2026 Share Award Scheme, including its mandate limits and sublimits, is a material corporate action that could affect share value due to potential dilution and changes in incentive structure. The authorization of the Board to manage the scheme further streamlines the process, which may impact investor confidence in the company’s governance and execution capabilities. Shareholders are advised to review the full circular dated March 9, 2026, for comprehensive details before voting.

Contact Information

• Address: Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., No. 23, Eighth Street, Baiyang Street, Qiantang District, Hangzhou, Zhejiang Province, PRC, Postal Code: 310018
• Contact Person: Mr. Hu Rong
• Email: [email protected]

Conclusion

The upcoming EGM and its resolutions, especially the proposed share award scheme and related authorizations, represent significant corporate actions with the potential to influence the company’s share structure and price. Investors should closely monitor the developments and participate in the voting process to safeguard their interests.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should consult the official company documents and seek professional advice before making any investment decisions related to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

View JIUYUAN GENE Historical chart here